Streetbeat News

Revenues

TDOC

13 analysts have recently updated their ratings and price targets for Teladoc Health (NYSE:TDOC), showing a mix of bullish and bearish sentiments. The average 12-month price target was adjusted to $21.15, marking an 18.37% decrease. The adjustments reflect changing market dynamics and Teladoc Health's performance, including a positive revenue trend with a growth rate of 3.58% as of December 31, 2023, but lagging behind industry peers. Despite a strong net margin and ROA, the company's debt management poses a challenge with a higher than average debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 5:00 pm

OII

Four analysts have recently shared their views on Oceaneering International (NYSE:OII), with sentiments ranging from bullish to indifferent. The average 12-month price target for OII is now $28.5, marking a 23.91% increase from the previous target of $23.00. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their perspectives on the company's performance and market conditions. Oceaneering International, serving various industries including offshore energy and defense, has shown impressive revenue growth and ROE, but faces challenges in net margin and debt management.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 5:00 pm

CFR

Cullen/Frost Bankers (NYSE:CFR) received mixed analyst ratings over the past quarter, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for CFR has been raised to $120.56, indicating a 2.67% increase from the previous target. Analysts from firms like Wedbush, RBC Capital, and JP Morgan have updated their ratings and price targets, reflecting various adjustments based on market conditions and company performance. Despite facing challenges such as a decline in revenue growth and below-average net margin, CFR's strong ROE and conservative debt management are highlighted as positive aspects.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 5:00 pm

BMY

Analysts have recently provided diverse opinions on Bristol-Myers Squibb (BMY), with all maintaining an 'Indifferent' stance over the past quarter. The average 12-month price target for BMY has been adjusted to $50.00, marking a 15.61% decrease from the previous target of $59.25. This adjustment reflects changes in market dynamics and company performance. Despite a positive revenue trend and strong net margin, BMY faces challenges in ROE and relies less on debt financing compared to industry averages.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 5:00 pm

ENVX

Enovix (NASDAQ:ENVX) has received mixed analyst ratings over the past three months, with a recent shift towards a more bullish outlook. The average 12-month price target for ENVX has increased by 25.56% to $22.6, reflecting positive sentiment. Analyst actions include adjustments to ratings and price targets, with notable mentions from JP Morgan, Cantor Fitzgerald, EF Hutton, and Canaccord Genuity. Enovix's financial performance shows significant revenue growth but challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 4:01 pm

EQT

EQT Corp (NYSE:EQT) has been analyzed by 25 analysts, showing a mix of ratings from bullish to bearish. The average 12-month price target is $41.8, a slight decrease from the previous $42.14. Analyst actions include various adjustments to ratings and price targets, reflecting changing market dynamics and company performance. EQT, a natural gas production company, faces challenges with a -28.89% revenue decline and below-average profitability metrics. Despite a balanced debt approach, its financial performance lags behind industry averages.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 4:01 pm

KREF

Recent analyst ratings for KKR Real Estate Finance (NYSE:KREF) show a shift towards a more cautious outlook, with a notable decrease in the average 12-month price target from $12.00 to $10.95, reflecting an 8.75% drop. Analysts from firms including Keefe, Bruyette & Woods, JP Morgan, Wells Fargo, and JMP Securities have lowered their price targets and ratings, indicating concerns over the company's market position, revenue trends, and financial health. KKR Real Estate Finance's financial indicators such as revenue growth, net margin, ROE, ROA, and debt management suggest potential challenges ahead.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 4:00 pm

ASB

Analyst opinions on Associated Banc (NYSE:ASB) show a diverse range from bullish to bearish, with a recent shift towards a more positive outlook. Over the past quarter, 6 analysts have provided ratings, with the majority being indifferent. However, recent updates show a positive trend in price targets, with an average 12-month target of $23.17, reflecting a 10.33% increase from the previous $21.00. This change is supported by specific analysts from firms like Stephens & Co., Barclays, Wells Fargo, RBC Capital, and Raymond James adjusting their price targets upwards. Associated Banc's financials indicate challenges in revenue growth, profitability, and asset utilization, with significant declines in revenue and net margin, and below-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 4:00 pm

VLY

Valley National Bancorp (NASDAQ:VLY) received mixed analyst ratings with a shift towards a more cautious outlook. The average 12-month price target was adjusted to $9.21 from $10.83, indicating a 14.96% decrease. Analysts from firms like Wedbush, RBC Capital, JP Morgan, Citigroup, Barclays, and Morgan Stanley have updated their ratings and price targets, reflecting concerns over the company's recent performance, including a -13.22% revenue decline and challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 4:00 pm

NWL

Newell Brands Inc. (NWL) shares rose after reporting Q1 earnings at the break-even point, surpassing analyst expectations of a 7-cent loss. Q1 revenues of $1.653 billion also exceeded forecasts, despite an 8.4% drop in net sales year-over-year. The company saw improvements in gross and operating margins and increased operating cash flow. Newell announced an organizational realignment expected to save $65-$90 million annually, with $55-$70 million in savings in 2024. However, it forecasts a Q2 sales decline of 9%-7% and EPS below analyst expectations.

Portfolio Pulse from Nabaparna Bhattacharya

April 26, 2024 | 3:58 pm